Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight " Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Non-Small Cell Lung Cancer Market Share @ Non-Small Cell Lung Cancer Market Outlook
Key Takeaways from the Non-Small Cell Lung Cancer Market Report
In April 2025, Merck Sharp & Dohme LLC announced a Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC).
In April 2025, Allist Pharmaceuticals Inc. conducted a phase 3 study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.
In April 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC.
About 10–15% of all lung cancers are SCLC, and about 80–85% are Non-Small Cell Lung Cancer.
In the US, in 2024, there were approximately 204,800 new cases of NSCLC cancer (~115,500 in men and ~89,300 in women.
The three main histological subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the US, approximately 59% of all lung cancers are adenocarcinomas. About 25% of all lung cancers are squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 6% of all lung cancers.
Among the age-specific contribution, age =65 years are affected more by NSCLC than age
In 2024, the total incident cases of NTRK1/2/3 gene fusion NSCLC in the US was around 450.
In biomarker specific specific cases, most number of cases is from PD-L1 followed by KRAS, EGFR. On the other hand, NTRK accounted for least number of cases whereas, BRAF accounted for approximately 5% cases.
The two main subtypes of KRAS NSCLC are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~4,900 comprised of KRAS G12C, and ~13,300 comprised of KRAS non-G12C in 2024.
The increase in Non-Small Cell Lung Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
As per DelveInsight analysis, the Non-Small Cell Lung Cancer Market is anticipated to witness growth at a considerable CAGR.
The leading Non-Small Cell Lung Cancer Companies such as Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others.
Promising Non-Small Cell Lung Cancer Pipeline Therapies such as Amivantamab, Lazertinib, Pemetrexed 500 mg, Cisplatin, Gemcitabine, Furmonertinib 80 mg, ILX651 and others.
Stay ahead in the Non-Small Cell Lung Cancer Therapeutics Market with DelveInsight's Strategic Report @ Non-Small Cell Lung Cancer Market Outlook
Non-Small Cell Lung Cancer Epidemiology Segmentation in the 7MM
The epidemiology section of Non-Small Cell Lung Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Total incident cases of NSCLC
Gender-specific cases of NSCLC
Age-specific cases of NSCLC
Total incident cases of NSCLC by histology
Total cases of NSCLC by stages
Total incident cases of NSCLC by genetic mutation/biomarkers
Line wise Treated Cases of Metastatic NSCLC
Download the report to understand which factors are driving Non-Small Cell Lung Cancer Epidemiology trends @ Non-Small Cell Lung Cancer Prevalence
Non-Small Cell Lung Cancer Marketed Drugs
KEYTRUDA (pembrolizumab): Merck
KEYTRUDA is a PD-1-blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-L1. KEYTRUDA was first approved in October 2015 by the US FDA as a monotherapy for metastatic NSCLC. Later, the labels were expanded in 2016, 2017, 2018, and in 2023. In October 2023, the FDA approved KEYTRUDA platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent KEYTRUDA as post-surgical adjuvant treatment for resectable (tumors =4 cm or node positive) NSCLC. The drug has also received approvals in EU4 and the UK (August 2016) and Japan (December 2016), where the labels were expanded as well. Recently in September 2024, Merck announced that the MHLW has approved new indications for KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment. Earlier in March 2024, Merck announced that the EC has approved KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment
TECENTRIQ (atezolizumab): Genentech/Roche
TECENTRIQ is a PD-L1-blocking antibody. It is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin with a calculated molecular mass of 145 kDa. According to Roche's recent product development portfolio published in October 2024, the company anticipates submitting a filing for TECENTRIQ in the periadjuvant treatment of NSCLC in 2025.
Non-Small Cell Lung Cancer Emerging Drugs
Telisotuzumab vedotin: AbbVie
Teliso-V is an investigational antibody–drug conjugate targeting c-Met, a receptor tyrosine kinase overexpressed in tumors, including Non-small Cell Lung Cancer. Teliso-V has the potential to become an important new treatment option in non-small cell lung cancer, with an anticipated approval in 2L+ NSCLC in 2024. In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.
Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of the most advanced programs in AstraZeneca's ADC scientific platform and one of the three leading ADCs in the oncology pipeline of Daiichi Sankyo. In January 2023, a Phase III clinical trial, combined with immune checkpoint inhibitors for the first-line treatment for Non-Small Cell Lung Cancer without actionable genomic alterations, PD-L1 <50% (trial name: TROPION-Lung07), was initiated. No TROP2-directed therapies are currently approved for treating Non-Small Cell Lung Cancer patients. AstraZeneca and Daiichi Sankyo are interrogating Dato-DXd in 1L non-driver mutation patients with TROPION-Lung08 (trying to knock off the Keynote-024 regimen) and with TROPION-Lung07 (trying to dethrone Keynote-189 regimen, the most important indication for Merck's KEYRTUDA), as well as covering 2L and 3L patients with TROPION-Lung01.
To learn more about Non-Small Cell Lung Cancer treatment guidelines, visit @ Non-Small Cell Lung Cancer Treatment Market Landscape
Non-Small Cell Lung Cancer Market Outlook
As more targetable mutations are discovered, and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.
Non-Small Cell Lung Cancer Drugs Uptake
The existing NSCLC treatment is mainly dominated by targeted therapies for mutations such as EGFR-sensitizing mutations, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, BRAFV600E mutation, MET exon 14 skipping mutations, RET fusions, and KRASG12C mutation. EGFR mutations and ALK rearrangements are well-known genetic abnormalities that drive the development of NSCLC. The use of TKIs as a treatment approach has shown better results in terms of patient outcomes when compared to chemotherapy. EGFR mutations are frequently observed, EGFR exon 19 deletions and EGFR exon 21 L858R mutations. The FDA has approved various TKIs to treat these mutations, with TAGRISSO considered the standard treatment. GILOTRIF is approved for patients with other EGFR sensitivity mutations like S768I, L861Q, and G719X.
Major Non-Small Cell Lung Cancer Companies
Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others.
Scope of the Non-Small Cell Lung Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Non-Small Cell Lung Cancer Companies- Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others
• Non-Small Cell Lung Cancer Pipeline Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, Cisplatin, Gemcitabine, Furmonertinib 80 mg, ILX651 and others.
• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer Market Drivers and Barriers
• Non-Small Cell Lung Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Content
1. Key Insights
2. Non-Small Cell Lung Cancer Executive Summary
3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis
4. Non-Small Cell Lung Cancer: Market Overview at a Glance
5. Non-Small Cell Lung Cancer: Disease Background and Overview
6. Patient Journey
7. Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Small Cell Lung Cancer Unmet Needs
10. Key Endpoints of Non-Small Cell Lung Cancer Treatment
11. Non-Small Cell Lung Cancer Marketed Products
12. Non-Small Cell Lung Cancer Emerging Therapies
13. Non-Small Cell Lung Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Non-Small Cell Lung Cancer Market Outlook
16. Access and Reimbursement Overview of Non-Small Cell Lung Cancer
17. KOL Views
18. Non-Small Cell Lung Cancer Market Drivers
19. Non-Small Cell Lung Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Global News
a day ago
- Global News
Canadian, European space agencies reaffirm relations amid political, economic anxiety
Economic and geopolitical turmoil is forcing the Canadian and European space agencies to work together more closely, the organizations' leaders said Friday as they signed a joint statement reaffirming their long-standing collaboration. At the Canadian Space Agency's headquarters south of Montreal, Josef Aschbacher, director general of the European Space Agency, said economic uncertainty and global conflict are pushing Europe's space sector to establish its autonomy — and reassert links with allies. 'If we are aiming to be more … independent, this does not mean that we want to isolate ourselves,' Aschbacher said. 'We want to be strong and autonomous in order to have partnerships with other agencies.' Canada is the European agency's only non-European co-operating state, and as such Canadian companies are granted privileged access to Europe's space market. Lisa Campbell, president of the Canadian Space Agency, said every dollar awarded to Canadian firms generates three dollars in return. Story continues below advertisement Leaders at both organizations signed a joint statement Friday reaffirming the agencies' close ties; Canada has had a deal with the European Space Agency since 1979. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Aschbacher's two-day visit to Canada is the first in a quarter century by a European space chief and included discussions with government and industry leaders. Defence spending is rising across the globe, and the United States is pressuring NATO members to increase their spending on defence, he said. 'We should not forget that defence is tightly linked with space because you do need communication, Earth observation capabilities and many other space technologies in order to work hand in hand.' As well, Aschbacher added that the United States' space agency — NASA — could be facing deep budget cuts. 'You have all seen the budget proposals that have been released as a very first proposal of the White House,' Aschbacher said. 'I can only say this is a work in progress: the budget negotiations are ongoing, but be assured that Europe and the European Space Agency will get out of this stronger, more autonomous, more independent.' Campbell said that in uncertain times it's important to reaffirm relationships with like-minded allies. Canada is a spacefaring nation, she added, from rovers to instruments to robotics that will be in demand around the world in low Earth orbit and in deep space. Canada is already a partner with NASA and ESA in the James Webb Telescope, the world's most powerful telescope. Story continues below advertisement 'We're resilient because we're quite confident that there's going to be a growing need for what we do in low Earth orbit and in deep space,' Campbell said. With a need for independent access to space, nascent launch capability involving commercial firms on the East Coast could come into play, she said. 'It's just a matter of time before Canada is a launching nation as well.'
Cision Canada
2 days ago
- Cision Canada
Canada reaffirms international collaboration with the European Space Agency Français
LONGUEUIL, QC, June 6, 2025 /CNW/ - Today, Sherry Romanado, Parliamentary Secretary to the Minister of National Defence, on behalf of the Honourable Mélanie Joly, Minister of Industry and Minister responsible for the Canadian Space Agency (CSA), joined CSA President Lisa Campbell and the Director General of the European Space Agency (ESA), Dr. Josef Aschbacher, at the John H. Chapman Space Centre (the CSA's headquarters in Longueuil). The two heads of space agencies signed a joint statement reaffirming Canada and ESA's unique, proven and productive partnership. This signature marks a key milestone in the mid-term review of the Canada–ESA Cooperation Agreement. For nearly 50 years, the Canada–ESA Cooperation Agreement has advanced Canadian innovation and expertise on the world stage. Canada's unique status as ESA's only non-European cooperating state gives Canadian companies privileged access to the European space market. Every dollar awarded to Canadian companies through ESA contracts generates nearly three dollars in return, benefitting Canadian businesses and injecting value into the Canadian economy. This collaboration helps Canada's space sector build long-term relationships with the European space community and contributes to strengthening innovation, competitiveness, and technological capabilities. It has propelled numerous Canadian organizations to the forefront of their fields, positioning Canadian expertise at the heart of bold international space missions. Dr. Aschbacher's visit to Canada was a unique and timely opportunity to underscore the deep ties between the space programs of Canada and Europe and to emphasize the shared commitment to fortifying their alliance in order to accelerate and grow their respective space sectors. As Canada looks to strengthen its ties with like-minded countries, including those in Europe, this longstanding partnership provides an opportunity and a proven path for Canada to bolster diversification of the space sector for the benefit of Canadians. Quotes "Today's signature is about reaffirming Canada's long-standing commitment to its collaboration with ESA, which has consistently yielded proven results for our Canadian space sector. As our focus is to unleash a new era of growth for our country, space represents the perfect domain to advance innovation and contributes to our goal of building a stronger Canada." — The Honourable Mélanie Joly, Minister of Industry and Minister responsible for the Canadian Space Agency "With this signature and the creation of the ESA–CSA task force, we are finding even more common synergies between ESA's activities and Canada's own priorities and strengthening the long-standing relationship between Europe and Canada. Canada's status as a non-European ESA cooperating state positions Canadian expertise – and industry – at the heart of bold international space missions. In today's geopolitical and economic environment, strong and reliable partnerships are more important than ever. ESA is proud to partner with Canada, and I look forward to our continued successes together." — Dr. Josef Aschbacher, Director General of the European Space Agency Quick facts Funded by the CSA, the Canada–ESA program allows Canadian organizations access to contracts related to ESA programs. Between January 2018 and December 2024, this collaboration led to 233 ESA-funded contracts to 82 Canadian entities, valued at approximately CAN$192 million. Behind these numbers is a growing network of Canadian talent and technology now woven into ESA's most advanced programs – from space robotics to next-generation communications. Canada and ESA have been collaborating in the space sector since the early 1970s. Formal cooperation began in 1979 with the signing of the first Cooperation Agreement. The Agreement has been renewed five times since (1984, 1989, 2000, 2012 and 2019). Dr. Josef Aschbacher's official visit to Canada took place from June 4 to 6, 2025. It included engagements with senior government officials and industry leaders in Ottawa and Montreal. Links SOURCE Canadian Space Agency
Cision Canada
2 days ago
- Cision Canada
HIGH LINER FOODS ACQUIRES LEADING U.S. BREADED AND BATTERED SEAFOOD BRANDS MRS. PAUL'S AND VAN DE KAMP'S FROM CONAGRA BRANDS, INC. FOR USD $55 MILLION
Transaction secures existing contract manufacturing business bringing incremental volume, margin, synergies and growth opportunities Estimated to deliver USD $11 million annual run rate Adjusted EBITDA 1 from 2027, inclusive of current contract margin, incremental contribution margin and net cost synergies, with potential for further growth Further diversifies the High Liner Foods portfolio adding market leading brands sourced from high quality Alaskan White Fish, produced in U.S. manufacturing facilities Positions High Liner Foods for scale in U.S retail with incremental sales opportunities afforded by complementary distribution profile and customer relationships (1) This is a non-IFRS financial measure. For more information on non-IFRS financial measures, see "Non-IFRS Financial Measures" in our Fourth Quarter 2024 Management's Discussion and Analysis ("4Q2024 MD&A"). LUNENBURG, NS, June 6, 2025 /CNW/ - High Liner Foods Incorporated (TSX: HLF) ("High Liner Foods" or "the Company"), a leading North American value-added frozen seafood company, today announced it has entered into a purchase agreement to acquire the Mrs. Paul's and Van de Kamp's brands of frozen breaded and battered fish products from Conagra Brands ("Conagra") for USD $55 million, inclusive of approximately USD $36 million in inventory. The purchase price is subject to a customary inventory adjustment. "This is a highly strategic and compelling opportunity for High Liner Foods that will serve as a catalyst for further growth in the U.S retail market," said Paul Jewer, President and Chief Executive Officer of High Liner Foods. "By taking full ownership of these well established and respected brands, we will capture additional value for our shareholders and ensure a seamless transition for existing customers. We look forward to offering choice and value to an expanded portfolio of customers and consumers in the growing U.S market." High Liner Foods currently co-manufactures products for Mrs. Paul's and Van de Kamp's brands at its U.S based manufacturing facilities, an average of 25 million pounds annually. Today's transaction secures the volume associated with the Company's current contract with Conagra which is due to expire in 2027. It is anticipated to increase High Liner Foods' annual volume from this business to a total of approximately 29 million pounds of fish procured, processed and sold in the U.S, aligned with the Company's strategy to continue to diversify its global supply chain. Before reaching the anticipated annual run rate of USD $11 million Adjusted EBITDA in 2027, which is inclusive of current contract margin, incremental contribution and synergies, the transaction is anticipated to generate incremental Adjusted EBITDA for 2026 of approximately USD $4 million on top of existing contract margins. The Company anticipates approximately 12 – 18 months of ramp-up time to realize synergies from across the Company's operations which are reflected, after transaction costs, in the estimated annual run rate from 2027 onwards. The transaction is expected to be slightly accretive to Adjusted EBITDA starting in the second half of 2025. Mrs. Paul's and Van de Kamp's are leading brands in the frozen breaded and battered category in U.S retail with high consumer awareness. High Liner Foods intends to leverage the brands' strong conversion metrics and brand equity to drive incremental sales of its diversified portfolio of branded and value-added retail products through an expanded distribution network and a significant national base of new retail customers. The Company will fund the transaction from its existing ABL facility. The transaction is expected to close at the end of June 2025, subject to customary closing conditions. Mr. Jewer concluded, "This strategic transaction is one example of the steps we are taking to position High Liner Foods for future growth, leveraging our healthy balance sheet today to secure profitable volume and incremental growth for years to come. We have a clear line of sight to significant synergies that will strengthen our performance over time through operational efficiencies and incremental sales opportunities." Advisors BMO Capital Markets acted as exclusive financial advisor to High Liner Foods in connection with the transaction. Goodwin Procter LLP served as legal counsel to High Liner Foods. Non-IFRS Measures The Company reports its financial results in accordance with International Financial Reporting Standards ("IFRS"). Included in this press release are the following non-IFRS financial measures: Adjusted EBITDA. The Company believes this non-IFRS financial measure provides useful information to both management and investors in measuring the financial performance and financial condition of the Company for the reasons outlined below. This measure does not have any standardized meaning as prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other publicly traded companies, nor should it be construed as an alternative to other financial measures determined in accordance with IFRS. Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization adjusted for items that are not considered representative of ongoing operational activities of the business. We use Adjusted EBITDA as a performance measure as it approximates cash generated from operations before capital expenditures and changes in working capital, and it excludes the impact of expenses and recoveries associated with certain non-routine items that are not considered representative of the ongoing operational activities, as discussed above, and share-based compensation expense related to the Company's share price. We believe investors and analysts also use Adjusted EBITDA to evaluate the performance of our business. The most directly comparable IFRS measure to Adjusted EBITDA is "Net income" on the consolidated statements of income. Adjusted EBITDA is also useful when comparing to other companies, as it eliminates the differences in earnings that are due to how a company is financed. Also, for the purpose of certain covenants on our credit facilities, "EBITDA" is based on Adjusted EBITDA, with further adjustments as defined in the Company's credit agreements. For a reconciliation of Adjusted EBITDA to net income, refer to the Company's MD&A for the fifty-two weeks ended December 28, 2024 which is available on SEDAR+ at Forward Looking Statements This press release contains forward-looking information within the meaning of applicable securities laws, including, but not limited to, statements regarding the Company's acquisition of the Mrs. Paul's and Van de Kamp's brands and associated inventories, the expected timing for closing such acquisition, the anticipated benefits and synergies from such acquisition, the future financial and operational performance of the Company and the business to be acquired, including Adjusted EBITDA, financing of the acquisition, and the business strategies and operational activities of the Company and the markets and industries in which it operates. Forward-looking statements are based on information currently available to the Company and management's estimates, expectations and assumptions, which we believe are reasonable as of the current date but may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information include, but are not limited to: availability, demand and prices of raw materials, energy and supplies; expectations with regards to sales volume, earnings, product margins, product innovations, brand development and anticipated financial performance; the ability to develop new and innovative products that result in increased sales and market share; the maintenance of existing customer and supplier relationships; manufacturing facility efficiency; the ability of the Company to reduce operating and supply chain costs; the condition of the Canadian and American economies; product pricing; foreign exchange rates, especially the rate of exchange of the CAD to the USD; the ability to attract and retain customers; operating costs and improvement to operating efficiencies; interest rates; continued access to capital; the competitive environment and related market conditions; the ability of the Company to execute and integrate the acquisition; and the general assumption that none of the risks identified below will materialize. Forward-looking statements are also subject to risks and uncertainties, including, but not limited to, risks relating to the inability to successfully transition and integrate the business acquired following closing, the risk that the acquisition may not be completed in a timely manner or at all, risks related to a failure to obtain financing by the Company on acceptable terms, the potential failure to realize anticipated synergies and other benefits from the proposed transaction, customer risk, geopolitical and tariff risks, and uncertainty and adverse changes in general economic conditions and consumer spending habits. Actual results or events may differ materially from those expressed or implied by such forward-looking statements. Additional information about these and other assumptions, risks and uncertainties is included in the Company's securities regulatory filings, including under the headings "Risk Factors" and "Forward-Looking Information" in the Company's annual Management's Discussion & Analysis, which can be found under the Company's profile on SEDAR+ at Undue reliance should not be placed on this forward-looking information, which applies only as of the date hereof, and the Company does not undertake to update or revise any forward-looking information, whether as a result of any new information, future events or otherwise, except as may be required by applicable law. About High Liner Foods Incorporated High Liner Foods Incorporated is a leading North American processor and marketer of value-added frozen seafood. High Liner Foods' retail branded products are sold throughout the United States and Canada under the High Liner, Fisher Boy, Mirabel, Sea Cuisine, and Catch of the Day labels, and are available in most grocery and club stores. The Company also sells branded products to restaurants and institutions under the High Liner, Mirabel, Icelandic Seafood and FPI labels and is a major supplier of private label value-added seafood products to North American food retailers and foodservice distributors. High Liner Foods is a publicly traded Canadian company, trading under the symbol HLF on the Toronto Stock Exchange. For further information about the Company, please visit our website at or send an e-mail to [email protected]. SOURCE High Liner Foods Incorporated
